ࡱ> Root Entryn cL"@&FileHeader=DocInfoWHwpSummaryInformation.O!#$%',()*+&-./012345Root Entryn cL@&FileHeader=DocInfoWHwpSummaryInformation.O  8] <\><The CMC opportunity for Korea Biotech: Choosing the best CDMO for IND Phase I> <\Դ><Recently, technological improvement has been intensified to meet the complex structures and difficult-to-express proteins such as ADC, Multi-specific antibody or fusion protein, etc. With these issues, there are increasing tasks to high throughput technology, supply demand, low manufacturing cost and less regulatory concerns. Each pharmaceutical company should have a capability of process development to increase the productivity of various types of biologics, but due to the limit of capacity, it is necessary to outsource some work scopes. SBL s CDO service launched at 2018, has a work scope from gene to IND filing with excellent resources as well as technologies in very short period. By client satisfaction and outcome of service quality aiming global standard, it has been noted that the operation excellence in SBL CDO is also addressed beyond proven SBL CMO capability. In this conference, the detail of our>GIF89aɻxxxkkk]]]PPPCCC555((( d`LH00`Hذ̘`H0|pdXL@`0H `H0`dHL`H0xp`XH@0d LȰ``HH00dLؘȀ`H0xp`XH@d0L `H0d`LH`H0|pdXL@0`$H`dHL00`HذȘdL0xp`XH@0` HdH0ȳ``HHdL0xp`XH@`0H Ը̰ĠऀؘpȈXxHp@h@d8`8X0xT0pH dxddxd`d`p`|``x`p``x`!, H*\ȰÇ#JHŋ3jȱǏ CIɓ(S\ɲ˗0cʜI͛8sɳϟ@ JѣH*]ʴӧPJJիXjʵׯ`ÊKYv`ZgoU\mҤ__xK_+^xǐ#KLyaf~x7s=%6t^K'|-]Gp۷_ۭmؿ [vw|fl׸ft1fW׸qnO)nVx\jSǣs麀W/V%a&h h/Hu`pQD[v5W[~a>}Wj~.)X.b7QV I` ʄuEG}Xwʹ$o*.bu  yiiyya}qHej$--Zbsŕi"G߆#"z~&Gb5Fˆ!D>hFRH ^݇ >8lr>h'gn}Vz:}gXjizBj袜9H\Cmcagړewjhz&'w϶ҫaz`ikbmExgӎkv%n /jlf:Vy&K)l({2k6ٱgglfl&;1**+m 3kZx&2;Kvq6ޑz' ӊ +Sm]p֮*ť!}.~ǵEr8r1Wr-jdʪdj1=x']M37pbS %|ZtIy`xqX"O~qW7/iyrͶ}|u8b튗:{پ=7?skܙM;!Ǹ=\`+_.x WΊ෹uf~Z@V8zC 6p &/}HWP Document FileRu4 BU6A66U/|."ϊA=m#cH%ni#auHhb \ZXY4PWE!< gyaT&pd9ƒrT (L$-;gQn_6 ?Q;A[y)fiAbG]$$yĔpWL:WKq)$7wIx^\=|*et?PW tE)zBP-*QPRGP^c#JIk v<5bt>XLe^ELgj>DD'3o*M(Nm-5vM O)FA=YQTꬔ'\ϹnK^=MIjoU(R*:4ݫJr2VG!lJiɢuu:7

k̨Vd}bYteZZ~6p܈.''f\'eq=*ƽ.OZ}.o)ͦiEvJ7sZl~  ^zW#0[k^H]iTI5B1ש:kO *#δDV&1TkfU k.lVV[v[`2*!-(r2b$ZM0i*:npNr3 +Q<߂ُ5< إͲSQ,4iUof yh}zWRvhK./;OWMVհgMZָεw^MbNf: ;`a``a`0x  X d p|ajou2010D 2 10| ”| $ 2:36:28ajou8, 5, 8, 1555 WIN32LEWindows_7@m @PbL@VAkA~$mjы=VR[x,hF4"b7xP zzR!=zP<蛙]Mv춚 e;y7ofggT`P!֕rvv0EC1jBuc 3L 8pBfdO[ ;~53hh)v^I + ǰ/7h5Qz .1eAc- Ѽspf@,~ԸVB .U Ɯ$:{؝ 9ey묟 +9(^vHh><P]YTAxCO{(W|ͫb,C8U)x/[qo5:z˪nleo{l/dܙ޶J|`l{eo*}I4z73/62WMhU>3$/H&(vQM`C5BZp${qC(E AD,\vh7n,B\ȢTΝL3w{;7M09,K{<3N׶)Æ!ot<ln_ :P9Sv蠶 Iq@i}gwx(ASOdy&$Y-~^-tX?, G-76< 6t>(g;NFiQ jU]QsԋVƋ.3m[v3m[z–чplQ) ) uϺA7_)d_h_?NH%5бd~M.~Nc7/z-6IVSl:n7ԬB hѩ ңy,ꎼIe Y -psFk֨NMjQ*o0}4Ρi|H>K9 )eԨ3UZaJ/oG3{-fdLsu+-uCpQljmꇆkiɢ|޸ZI\_N8qn\$V׬B{:o4 !"#$%&'()*+,-./0123456789:;<A>?@BCDEFGHIJKLMNPQRSTUVXYZ[\]^_`abcdefghiklopqrstuvxyz{|}~BodyText @ibLPbLPrvImage PrvTextDocOptions n cLn cLSection0wZ"={T!:&EqB#UeGV8J>{< rLm3תY隈h"M|K@zWDgȎxuƖՁ wBJЬktchR."\+X`dUXNW*f[J,/˼W'RN&"X@\sEo2*52+ԯe[IvMZq[o[ :&[%quL$ |A:v1Jd&2li./8.}i>y;|۰$gҺ#<'-yRʶ5YQR j8 ,Y燢atP99*,w6l@G͆ o#(a6=4J&/_Gkǡudʬa:x\V񵎬߄}3Fl> &;#|MGܧq)N5:6LM_mAp%>=A lxxxK:rCD"}|sX6k=9f@e R+HFR/ gU Oߪ/ŕkQg_vC6J `DcA(6ZR@MU҃`B*RBeWMhE67!GC(ۘ $!>ߙ7SWfm¡A _)C[UH8@h>fD fMLCI4Lyg̲yv!)yON܌tɉ~PUO -vԩ ]9LqmYU D44]$tMWb> n\P 菺$H)fݬ<1xlx:W##> x` e~mfן 3 9Vu)2[ԧ-4FGlH}ҿNƣ/=nyI4gڰC n{^m(17Ne T2)v'syxa?7bbY޲7(l-d1)-R@2؊'eE8R"`_$9iN/,o8o}4j[M̿G}wձSGk}~8OA <\Ba_i\Ud)HI4,s, sh8If~I_"B>B9і4ȱv89)?@BCDEFGHIJKLMNPQRSTUVXYZ[\]^_`abcdefghiklopqrstuvxyz{|}~